Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Venture Life ( (GB:VLG) ) has provided an update.
Venture Life Group PLC has announced the sale of its contract development and manufacturing operations, along with certain non-core products, to BioDue S.p.A for €62 million. This strategic move allows Venture Life to streamline its operations, focusing on its higher-margin core brands and expanding its presence in key markets such as the UK, US, and Europe. The sale will provide significant financial resources to invest in existing brands and pursue further acquisitions, enhancing the company’s growth potential and positioning it as a pure play consumer healthcare brand platform.
More about Venture Life
Venture Life Group PLC is a leader in product innovation, development, and commercialization within the global consumer healthcare sector. The company focuses on providing preventative and treatment solutions to support a longer, healthier life, with a strong emphasis on women’s health and its core brands such as Balance Activ, Health & Her/Him, Lift, Earol, Pomi T, and Gelclair.
Average Trading Volume: 448,033
Technical Sentiment Signal: Buy
Current Market Cap: £57.62M
For an in-depth examination of VLG stock, go to TipRanks’ Stock Analysis page.